Aletaha D, Maa JF, Chen S, et al. - Data from two randomised controlled trials (larger study, N = 207; second trial; N = 67), in people with established RA receiving adalimumab + methotrexate were analyzed in order to ascertain whether disease duration and the number of former disease-modifying antirheumatic drugs (DMARDs) impact response to therapy in individuals with established RA. It was discovered that in individuals with established RA, the number of former DMARDs and disease duration affects responses to therapy. Moreover, the number of former DMARDs, irrespective of disease term, has a limiting impact on the possible response to adalimumab therapy.